Opening New Frontiers By Advancing The Promise of PI Signaling Pathways

Albert S. Yu, M.D.

Select a team to find out more

Albert S. Yu, M.D.

Albert S. Yu, M.D.

Chief Medical Officer

Dr. Albert Yu arrived at Petra Pharma in 2018 after spending four years working as an independent consultant.  Albert has 25 years of drug development experience across multiple therapeutic areas.  He has introduced over a dozen new drug candidates into clinical development and was also a key contributor to the development of two marketed drugs: Cialis® for the treatment of patients with erectile dysfunction and Zydelig® for the treatment of patients with chronic lymphocytic leukemia and follicular lymphoma.

Albert served as Vice President of Clinical Development at Omeros Corp. from 2012 to 2014, and previously, held the posts of Chief Medical Officer at Calistoga Pharmaceuticals, Inc. and Senior Director of Clinical Affairs at ICOS Corp.

Albert trained in internal medicine and pulmonary and critical care medicine.  He is a graduate of the University of Washington School of Medicine, where he earned an M.D., and the Massachusetts Institute of Technology.  Albert also serves on the scientific advisory board of OncoResponse, Inc.